Where are the inequalities in ovarian cancer care in a country with universal healthcare? A systematic review and narrative synthesis

Magnoflorine inhibits cisplatin-induced protective autophagy by down-regulating HMGB1 and increases drug sensitivity in drug-resistant ovarian cancer cells

“…The mortality of OC is the highest among gynecological malignancies [1] as it is commonly diagnosed at an advanced stage [15], and for which surgical intervention plus platinum combined with paclitaxel is the standard first-line treatment [3]. However, late-stage diagnosis and the development of drug resistance to chemotherapy are the primary factors contributing to the unfavorable prognosis [2]. While first-line treatments for OC often yield a high response rate and clinical remission [2], approximately 70% of OC cases experience recurrence, and tumors eventually acquire strong resistance to platinum-based chemotherapy [2].…”

“…However, late-stage diagnosis and the development of drug resistance to chemotherapy are the primary factors contributing to the unfavorable prognosis [2]. While first-line treatments for OC often yield a high response rate and clinical remission [2], approximately 70% of OC cases experience recurrence, and tumors eventually acquire strong resistance to platinum-based chemotherapy [2]. Abnormal DNA damage repair function, including nucleotide excision repair abnormalities, base mismatch repair abnormalities, DNA double-strand break damage repair abnormalities and cross-damage repair abnormalities, represent the main mechanisms of cisplatin resistance [2].…”

“…Ovarian cancer (OC) is a prevalent gynecologic malignancy [1], and its main form of treatment is cisplatin-based chemotherapy [2]. Ovarian cancer is a malignant tumor of ovarian tumor, which refers to the malignant tumor growing on the ovary, of which 90%~95% is the primary cancer of the ovary, and the other 5%~10% is the primary cancer of other parts of the ovary.…”

“…Early diagnosis of ovarian cancer is difficult due to the lack of specific symptoms, and the lack of effective screening. Most patients have advanced stage disease at the time of diagnosis [1,2]. However, resistance of OC cells to cisplatin has resulted in a 5-year survival rate of approximately 30% for OC patients with advanced stage disease [2].…”

“…Most patients have advanced stage disease at the time of diagnosis [1,2]. However, resistance of OC cells to cisplatin has resulted in a 5-year survival rate of approximately 30% for OC patients with advanced stage disease [2]. In addition, platinum resistance has emerged as a significant obstacle in the successful treatment of OC, and its underlying mechanisms remain unclear [3].…”